Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients - 01/10/22
Highlights |
• | Expert defined the diagnostic criteria of metabolic-associated fatty liver disease. |
• | The influence of steatosis on liver stiffness measurement. |
• | Fatty liver disease with dual or multiple causes is the existence of liver injury. |
• | Liver stiffness measurement is a good means of quantifying the stage of fibrosis. |
• | Liver stiffness measurement is affected by high controlled attenuation parameter. |
Abstract |
Background |
The impact of hepatic steatosis on liver stiffness measurement (LSM) in both chronic hepatitis B(CHB) and metabolic-associated fatty liver disease (MAFLD) remains controversial.
Aims |
To determine whether LSM is affected by hepatic steatosis in CHB-MAFLD.
Methods |
Hepatic steatosis and liver fibrosis were assessed by histological and noninvasively methods. The area under the receiver operating characteristic curve (AUROC) was used to evaluate the diagnostic performance of LSM.
Results |
The prevalence of MAFLD in CHB patients (n = 436)was 47.5% (n = 207). For patients with low amounts of fibrosis (F0–1 and F0–2), the median LSM was 8.8 kPa and 9.2 kPa in patients with moderate- severe steatosis,which was significantly higher than that in patients with none-mild steatosis (P < 0.05) . The positive predictive value(PPV) was lower for LSM identifying significant fibrosis (F ≥ 2) as well as severe fibrosis (F ≥ 3) in group which controlled attenuation parameter(CAP) ≥ 268 dB/m than its counterpart(68.2% vs 84.6% and 24.3% vs 45.0%). The AUROC of LSM detected F ≥ 2 was 0.833 at a cutoff of 8.8 kPa and 0.873 at a cutoff of 7.0 kPa in patients with CAP ≥ 268 and CAP < 268, respectively.
Conclusions |
The presence of moderate-severe steatosis, detected by histology or CAP, should be taken into account to avoid overestimation of LSM.
Le texte complet de cet article est disponible en PDF.Keywords : Liver stiffness measurement, Metabolic associated fatty liver disease, Hepatic pathological steatosis
Plan
| All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. |
Vol 46 - N° 8
Article 101957- octobre 2022 Retour au numéro
Article précédent
- Diagnostic accuracy of apparent diffusion coefficient values combined with γ-glutamyl transpeptidase-to-platelet ratio parameters for predicting hepatitis B-related fibrosis
- Xingxiang Liu, Jian Zhou, Liyao Zhu, Xin Zhang, Feng Li
- Clinicopathological assessment of steatohepatitic hepatocellular carcinoma
- Kenji Yamaoka, Satoshi Saitoh, Keiichi Kinowaki, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Toshio Fukusato, Hiromitsu Kumada
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?